Tags : RET-Mutant Medullary Thyroid Cancer

Eli Lilly Opens its P-III LIBRETTO-531 Clinical Trial for LOXO-292

Shots: The second P-III LIBRETTO-531 involves assessing of selpercatinib vs physician’s choice of cabozantinib or vandetanib in 400 patients in ratio (2:1) with advanced or metastatic RET-mutant MTC who have received no prior systemic therapy for metastatic disease The study will have efficacy endpoints as progression-free survival (PFS), treatment failure-free survival (TFFS), overall survival (OS), […]Read More